SLAMF6 Emerges as Novel Immune Checkpoint Target for Cancer Immunotherapy
Key Insights
Researchers at Université de Montréal have identified SLAMF6 (search) as a novel immune checkpoint molecule that functions autonomously on T cell surfaces to suppress anti-tumor immunity.
Unlike PD-1 (search) and CTLA-4 (search), SLAMF6 (search) operates through cis homotypic interactions on T cells themselves, accelerating T cell exhaustion independently of tumor cell interactions.
Monoclonal antibodies (search) targeting SLAMF6 (search) demonstrated enhanced T cell activation and tumor growth suppression in preclinical models, offering potential for patients resistant to current checkpoint inhibitors (search).
Researchers at Université de Montréal have identified SLAMF6 (search) (Signalling lymphocytic activation molecule 6) as a novel immune checkpoint molecule that functions as a critical suppressor of T cell-mediated anti-tumor responses. The discovery, published in Nature and led by Dr. André Veillette at the Montreal Clinical Research Institute (search) (IRCM), reveals a fundamentally different mechanism of immune suppression that could transform cancer (search) immunotherapy approaches.
Novel Mechanism of Immune Suppression
Unlike established checkpoint inhibitors (search) such as PD-1 (search) and CTLA-4 (search) that require engagement with tumor or stromal cells to dampen T cell activity, SLAMF6 (search) operates through an autonomous mechanism on the T cell surface. The research team demonstrated that SLAMF6 is triggered in cis by homotypic interactions at the T cell surface, eliciting inhibitory effects that suppress T cell activation and limit anti-tumor immunity independently of SLAMF6 expression on tumor cells.
"SLAMF6 (search) self-activates, transmitting inhibitory signals independent of tumor cell interaction," the researchers reported. This intrinsic mechanism not only weakens cytotoxic attack capacity but also impairs the generation of durable, resilient T cell populations capable of sustained tumor control.
The molecule is preferentially expressed on progenitor or stem-like exhausted T (Tpex) cells, but not on terminally exhausted T (Tex) cells, as demonstrated in mouse models. Importantly, Tpex cells retain the capacity for functional restoration after immune checkpoint blockade, making SLAMF6 (search) a particularly attractive therapeutic target.
Accelerated T Cell Exhaustion
SLAMF6 (search) signaling accelerates the progression toward T cell exhaustion, a dysfunctional state characterized by diminished cytokine production, proliferative capacity, and cytolytic activity. This state represents a major obstacle in cancer (search) immunotherapy, as exhausted T cells fail to eradicate malignant cells effectively.
The discovery provides crucial insight into why many patients show limited or transient responses to current checkpoint inhibitors (search) like PD-1 (search)/PD-L1 (search) blockers. By uncovering this internal immune brake, researchers have identified a previously hidden mechanism contributing to immunotherapy resistance.
Therapeutic Antibody Development
Capitalizing on these insights, the research team engineered monoclonal antibodies (search) designed to disrupt SLAMF6 (search) homotypic interactions on T cells. These novel biologics demonstrated impressive preclinical efficacy, with a robust ability to disrupt the cis interactions that strongly augmented T cell activation.
In murine tumor models, treatment with SLAMF6-neutralizing antibodies (search) resulted in enhanced infiltration of functional T cells, reduced immune exhaustion markers, and potent suppression of tumor growth. The antibodies led to a marked increase in T cell activation and proliferation, with effects that collectively surpass the efficacy of previously available SLAMF6 (search) targeting agents.
The monoclonal antibodies (search) against human SLAMF6 (search) reduced the proportions of exhausted T cells and inhibited tumor growth in vivo, demonstrating the therapeutic potential of this approach.
Clinical Implications and Future Directions
The implications of this research extend beyond current immunotherapy paradigms. By neutralizing an internally driven suppressive pathway, these antibodies represent a next-generation immunotherapeutic strategy that may complement or even supersede established checkpoint inhibitors (search).
Dr. Veillette emphasizes that the unique properties of SLAMF6 (search) inhibition could enable combination therapies that synergize with other immune modulators, potentially enhancing anti-tumor immunity beyond current limits. The approach offers particular hope to patients who have developed resistance or exhibited non-responsiveness to PD-1 (search)/PD-L1 (search) therapies.
The research team plans to advance these promising antibodies into early-phase clinical trials to assess their safety profile and therapeutic efficacy in diverse cancer (search) types, including both solid tumors (search) and hematological malignancies (search).
Paradigm Shift in Cancer Immunotherapy
This innovative approach represents a paradigm shift from exclusively targeting tumor-induced immune suppression toward addressing intrinsic immune regulatory checkpoints. The work demonstrates that SLAMF6 (search) functions exclusively as a T cell inhibitory receptor, which is triggered by cis homotypic interactions, positioning it as a promising target for therapies aimed at enhancing anti-tumor immunity.
IRCM's president, Dr. Jean-François Côté, described this discovery as a "new chapter in immunotherapy," highlighting the unprecedented ability to unmask and neutralize a previously hidden immune checkpoint. The breakthrough not only enhances molecular understanding of T cell regulation but also carries tangible potential to transform patient care worldwide.
The research was supported by leading Canadian funding bodies including the Canadian Institutes of Health Research (CIHR), the Terry Fox Research Institute (search), and the Canadian Foundation for Innovation (search), reflecting robust national commitment to advancing cancer (search) treatment landscapes.